Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) EBT (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed EBT for 16 consecutive years, with -$31.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 322.82% to -$31.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.9 million, a 57.9% decrease, with the full-year FY2025 number at $23.7 million, down 58.33% from a year prior.
  • EBT was -$31.2 million for Q4 2025 at Lemaitre Vascular, down from $22.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $22.9 million in Q3 2025 to a low of -$31.2 million in Q4 2025.
  • A 5-year average of $7.2 million and a median of $9.1 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 433.97% in 2023, then soared 153.84% in 2024.
  • Lemaitre Vascular's EBT stood at $7.8 million in 2021, then rose by 0.35% to $7.8 million in 2022, then tumbled by 433.97% to -$26.0 million in 2023, then skyrocketed by 153.84% to $14.0 million in 2024, then crashed by 322.82% to -$31.2 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's EBT are -$31.2 million (Q4 2025), $22.9 million (Q3 2025), and $18.1 million (Q2 2025).